Rentschler Biopharma SE, a global CDMO for biopharmaceuticals, appointed Benedikt von Braunmuehl Chief Executive Officer. Von Braunmuehl brings 30 years of experience in the global healthcare industry and has a track record of successfully implementing effective business strategies to achieve corporate growth goals. 

Prior to joining Rentschler Biopharma, von Braunmuehl served as CEO of HMNC Brain Health in Munich, Germany, where he transformed a research-focused organization to a clinical-stage biopharma company. Before this, he was COO Diagnostic Services at Medicover, where he streamlined processes, grew business lines, and significantly increased revenue. He previously worked at Qiagen, last serving as senior vice president, head of global commercial operations and member of the executive committee. In this position, he implemented several transformational projects and drove global commercial growth and efficiency initiatives.

Rentschler also appointed Tom Roberts President of Rentschler Biopharma Inc. and General Manager U.S. In this newly created role, Roberts will be responsible for leading the company’s U.S. business, including the site and operations in Milford, MA in Greater Boston. He also will join the company’s extended executive team.

Roberts has over 20 years’ experience in leading businesses. He was previously at Vitanova Biomedical, where he provided executive leadership, facilitated funding, and oversaw business and product development, regulatory compliance, manufacturing, and technology acquisition of a groundbreaking nanoparticle-based combination cancer therapeutic. Prior to this, he held leadership positions at Invictus Medical, 3M – KCI (Formerly Acelity) and Roche Diagnostics.

Nikolaus Rentschler, chairman of the supervisory board of Rentschler Biopharma SE, said: “I would like to warmly welcome Benedikt von Braunmuehl to Rentschler Biopharma. He has an impressive track record of effectively leading companies through rapidly changing market environments and transforming businesses to support sustainable growth. He has achieved this not only by improving efficiency, but also by focusing on client needs. He also brings a deep understanding of effectively scaling an international network of locations. Mr. von Braunmuehl is the perfect fit for leading Rentschler Biopharma, to continue transforming innovative ideas into life-saving biopharmaceuticals in the future.”

von Braunmuehl, said, “I am excited to have the opportunity to lead Rentschler Biopharma. The biopharmaceuticals market is slated to grow significantly in the coming years, and related companies are expected to increasingly focus on their core competencies. With these industry dynamics, the need for an experienced and reliable partner like Rentschler Biopharma, which can cover highly specialized industry demands in bioprocess development through to commercial manufacturing, is only going to grow.”

Regarding the appointment of Roberts, Rentschler said, “I am delighted today to welcome another strong addition to our executive team. Tom Roberts brings a wealth of experience in successfully growing businesses and building strong teams. He has important expertise in many facets of the life sciences industry, bringing a deep understanding of the needs in the field.”